key: cord-0816202-jul87ldo
authors: Moffa, Matthew A; Shively, Nathan R; Walsh, Thomas L
title: Characteristics of post-vaccination COVID-19 hospitalizations prior to booster vaccines
date: 2022-02-04
journal: Open Forum Infect Dis
DOI: 10.1093/ofid/ofac014
sha: de30e20711d8409be8f20d7a6b9dc99b62131722
doc_id: 816202
cord_uid: jul87ldo

This analysis describes clinical characteristics and outcomes of 128 fully vaccinated patients hospitalized with COVID-19 prior to booster vaccines. We found 27% were asymptomatic, 52% required ICU care, and 15% died from COVID-19. Most (89.2%) fully vaccinated patients hospitalized with symptomatic COVID-19 were ≥65 years old and/or severely immunosuppressed.

M a n u s c r i p t

Vaccination against SARS-CoV-2 plays in important role in reducing severe disease caused by Coronavirus disease 2019 . Data from Los Angeles County from May-July 2021 found that unvaccinated persons were 29.2 times more likely to be hospitalized for COVID-19 compared to fully vaccinated persons. 1 The overall age-adjusted vaccine effectiveness (VE) against hospitalization during that same time period in New York State was found to be 91.9%-95.3%. 2 Despite this high protection conferred from vaccination, post-vaccination hospitalizations do occur, although limited descriptive data exists. 3, 4 Importantly, these studies included time periods prior to the widespread emergence of the delta variant. We aimed to evaluate clinical characteristics and outcomes of fully vaccinated patients hospitalized with COVID-19 after the emergence of the delta variant, prior to the omicron variant, and prior to use of booster vaccines.

We conducted a retrospective review of all patients admitted with COVID-19 to 8 diverse western Pennsylvania hospitals (including both tertiary care and community based hospitals) within the Allegheny Health Network (AHN) between 7/15/21-8/31/21. Exempt status was granted by the AHN Institutional Review Board. Patients were identified using the electronic heath record (EHR) by extracting all patients with a positive SARS-CoV-2 test during the study time period, or if they had an active COVID-19 designation by the AHN infection prevention department for patients diagnosed outside the health system. Patients were included if they had COVID-19 during their hospitalization. Patients were excluded for age <18 years. Patients are not routinely tested for SARS-CoV-2 on admission at AHN, but only tested per the discretion of the treating provider, if a long term care facility protocol requires testing prior to placement, or a department protocol requires testing prior to a A c c e p t e d M a n u s c r i p t procedure. For patients with multiple hospitalizations, each admission was reviewed.

Demographic information, vaccination data, comorbidities, and clinical data were manually collected via review of the EHR, utilizing a standardized data collection instrument.

The primary aim was to describe the characteristics of fully vaccinated persons admitted with COVID-19. Secondary aims included determining estimated SARS-CoV-2 VE against hospitalization with COVID-19, need for intensive care unit (ICU) level care, mechanical ventilation, and in-hospital mortality. VE was estimated using the formula 1 minus (odds of vaccination among cases) / (odds of vaccination among population) using (Table 1) . Of the 35 patients who were asymptomatic for the duration of their hospitalization, 25 (71.4%) were tested due to placement in a long term care facility per protocols at most local skilled nursing facilities. A c c e p t e d M a n u s c r i p t VE against hospitalization, need for ICU care, mechanical ventilation, and in-hospital mortality for the entire cohort was estimated to be 84.5%, 85.1%, 86.6% and 83.1%, respectively. Vaccination was found to be over 91% protective against hospitalization for all age groups under 70. VE breakdowns by age are shown in Table 2 . There was no fully vaccinated patient under the age of 50 that needed mechanical ventilation or died from COVID-19.

Our report adds to the limited published data describing the clinical characteristics of fully vaccinated patients hospitalized with COVID-19 prior to booster vaccines. Juthani A c c e p t e d M a n u s c r i p t immunosuppressed, whereas we found 23.4% of our cohort to be severely immunosuppressed. 4 Importantly, our study was performed entirely during a time period where the delta variant constituted nearly all cases in the United States. 6 Also, no patients in our study had received a booster dose as they had yet to be widely authorized.

Our report also contributes to the large amount of data showing substantial protection from vaccination against hospitalization and death from COVID-19. According to the Centers for Disease Control and Prevention (CDC), fully vaccinated persons have consistently been hospitalized at a rate of <5 per 100,000 persons compared to unvaccinated persons hospitalized at a rate of >50 per 100,000 persons during our study time period. 7 We found that VE was lower amongst those ≥70 for protection against hospitalization, and those ≥80 for the need of ICU level care, relative to younger age groups. No fully vaccinated patient under the age of 50 required mechanical ventilation or died from COVID-19.

Our study has several important limitations. While data was collected among 8 different hospitals in AHN, they are all geographically located in western Pennsylvania, and findings may not be generalizable to other regions. Our health system does not test all patients for COVID-19 routinely on admission, but it is standard practice that patients are tested prior to placement in long term care. This is the reason for diagnosis in most of our asymptomatic cases, which may influence the characteristics of our total cohort relative to institutions with broader testing strategies. Because data for non-fully vaccinated patients with symptomatic COVID-19 were not available for this analysis, we were unable to calculate VE against symptomatic hospitalization. Our VE calculations were also unable to account for immunity from prior infection or partial vaccination in the group of non-fully vaccinated patients, which may underestimate VE. M a n u s c r i p t 14 (10.9) 9 (9.7) Autoimmune disease without active immunosuppressive therapy 10 (7.8) 6 (6.5)

Peripheral vascular disease 9 (7.0) 6 (6.5) Chronic liver disease 8 (6.3) 6 (6.5) Dementia 7 (5.5) 4 (4.3) Seizure 7 (5.5) 3 (3.2) M a n u s c r i p t 

SARS-CoV-2 Infections and Hospitalizations Among Persons Aged ≥16 Years, by Vaccination Status

New COVID-19 Cases and Hospitalizations Among Adults, by Vaccination Status

Hospitalisation among vaccine breakthrough COVID-19 infections

BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel

Pennsylvania Department of Health COVID-19 Vaccine Dashboard

Age-Adjusted Rates of COVID-19-Associated Hospitalizations by Vaccine Status in Adults Aged ≥18 Years

Accessed 26

M a n u s c r i p t A c c e p t e d M a n u s c r i p t M a n u s c r i p t